These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

698 related articles for article (PubMed ID: 34756241)

  • 21. [Clinical characteristics and prognostic factors of patients with Philadelphia-negative myeloproliferative neoplasm accelerated/blast phase].
    Yan X; Qin TJ; Li B; Qu SQ; Pan LJ; Li FH; Liu NN; Xiao ZJ; Xu ZF
    Zhonghua Xue Ye Xue Za Zhi; 2023 Apr; 44(4):276-283. PubMed ID: 37356995
    [No Abstract]   [Full Text] [Related]  

  • 22. Management of classical Philadelphia chromosome-negative myeloproliferative neoplasms in Asia: consensus of the Asian Myeloid Working Group.
    Gill H; Leung GMK; Ooi MGM; Teo WZY; Wong CL; Choi CW; Wong GC; Lao Z; Rojnuckarin P; Castillo MRID; Xiao Z; Hou HA; Kuo MC; Shih LY; Gan GG; Lin CC; Chng WJ; Kwong YL
    Clin Exp Med; 2023 Dec; 23(8):4199-4217. PubMed ID: 37747591
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The BCR-ABL1-negative myeloproliferative neoplasms: a review of JAK inhibitors in the therapeutic armamentarium.
    Griesshammer M; Sadjadian P
    Expert Opin Pharmacother; 2017 Dec; 18(18):1929-1938. PubMed ID: 29134817
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Molecular prognostication in Ph-negative MPNs in 2022.
    Vannucchi AM; Guglielmelli P
    Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):225-234. PubMed ID: 36485130
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Coexisting JAK2V617F and CALR Exon 9 Mutations in Myeloproliferative Neoplasms - Do They Designate a New Subtype?
    Ahmed RZ; Rashid M; Ahmed N; Nadeem M; Shamsi TS
    Asian Pac J Cancer Prev; 2016; 17(3):923-6. PubMed ID: 27039813
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Classical Philadelphia-negative myeloproliferative neoplasms: focus on mutations and JAK2 inhibitors.
    Helbig G
    Med Oncol; 2018 Aug; 35(9):119. PubMed ID: 30074114
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of Molecular Biology in Diagnosis, Prognosis, and Therapeutic Management of
    Abbou N; Piazzola P; Gabert J; Ernest V; Arcani R; Couderc AL; Tichadou A; Roche P; Farnault L; Colle J; Ouafik L; Morange P; Costello R; Venton G
    Cells; 2022 Dec; 12(1):. PubMed ID: 36611899
    [No Abstract]   [Full Text] [Related]  

  • 28. Application of an NGS-based 28-gene panel in myeloproliferative neoplasms reveals distinct mutation patterns in essential thrombocythaemia, primary myelofibrosis and polycythaemia vera.
    Delic S; Rose D; Kern W; Nadarajah N; Haferlach C; Haferlach T; Meggendorfer M
    Br J Haematol; 2016 Nov; 175(3):419-426. PubMed ID: 27447873
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Austrian recommendations for the management of essential thrombocythemia.
    Buxhofer-Ausch V; Heibl S; Sliwa T; Beham-Schmid C; Wolf D; Geissler K; Krauth MT; Krippl P; Petzer A; Wölfler A; Melchardt T; Gisslinger H
    Wien Klin Wochenschr; 2021 Jan; 133(1-2):52-61. PubMed ID: 33215234
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Myeloproliferative neoplasms: A decade of discoveries and treatment advances.
    Tefferi A
    Am J Hematol; 2016 Jan; 91(1):50-8. PubMed ID: 26492355
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Myelofibrosis: Genetic Characteristics and the Emerging Therapeutic Landscape.
    Tefferi A; Gangat N; Pardanani A; Crispino JD
    Cancer Res; 2022 Mar; 82(5):749-763. PubMed ID: 34911786
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Genetic Risk Assessment in Myeloproliferative Neoplasms.
    Tefferi A; Vannucchi AM
    Mayo Clin Proc; 2017 Aug; 92(8):1283-1290. PubMed ID: 28778261
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms.
    Vainchenker W; Kralovics R
    Blood; 2017 Feb; 129(6):667-679. PubMed ID: 28028029
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Diagnosis, pathogenesis and treatment of the myeloproliferative disorders essential thrombocythemia, polycythemia vera and essential megakaryocytic granulocytic metaplasia and myelofibrosis.
    Michiels JJ; Kutti J; Stark P; Bazzan M; Gugliotta L; Marchioli R; Griesshammer M; van Genderen PJ; Brière J; Kiladjian JJ; Barbui T; Finazzi G; Berlin NI; Pearson TC; Green AC; Fruchtmann SM; Silver RT; Hansmann E; Wehmeier A; Lengfelder E; Landolfi R; Kvasnicka HM; Hasselbalch H; Cervantes F; Thiele J
    Neth J Med; 1999 Feb; 54(2):46-62. PubMed ID: 10079679
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Individualizing Care for Patients With Myeloproliferative Neoplasms: Integrating Genetics, Evolving Therapies, and Patient-Specific Disease Burden.
    Mesa RA; Passamonti F
    Am Soc Clin Oncol Educ Book; 2016; 35():e324-35. PubMed ID: 27249739
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High Risk Janus Kinase 2 V617F Allele Burden in a Seven-Year Cohort of Patients with Myeloproliferative Neoplasms.
    Chatambudza M; Skhosana L; Ketseoglou I; Wiggill T
    Clin Lab; 2021 Nov; 67(11):. PubMed ID: 34758219
    [TBL] [Abstract][Full Text] [Related]  

  • 37. WT1 gene is overexpressed in myeloproliferative neoplasms, especially in myelofibrosis.
    Cottin L; Riou J; Boyer F; Bouvier A; Zannetti A; Blouet A; Truchan-Graczyk M; Jouanneau-Courville R; Beucher A; Ribourtout B; Orvain C; Hunault-Berger M; Blanchet O; Ugo V; Luque Paz D
    Blood Cells Mol Dis; 2019 Mar; 75():35-40. PubMed ID: 30612065
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Leukocytosis and MPNs: Where do we stand?
    Coltoff A
    Leuk Lymphoma; 2023 Mar; 64(3):564-572. PubMed ID: 36519233
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Disease modifying agents of myeloproliferative neoplasms: a review.
    Lee SE
    Blood Res; 2021 Apr; 56(S1):S26-S33. PubMed ID: 33935032
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Age-related macular degeneration and myeloproliferative neoplasms - A common pathway.
    Liisborg C
    Acta Ophthalmol; 2022 Oct; 100 Suppl 271(Suppl 271):3-35. PubMed ID: 36200281
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 35.